Lupin exceeded profit expectations in the second quarter, reporting a 74% surge in profits, reaching ₹8.53 billion. This growth was fueled by robust demand for their respiratory and diabetes medications. Overall revenue also saw an 11.3% increase, reaching ₹54.97 billion.
